Request Deal Involvement

Novozymes completed the acquisition of Chr. Hansen for $12.3bn.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Baker McKenzie

legal advisors

Baker McKenzie

Gorrissen Federspiel

legal advisors

Gorrissen Federspiel

Impact Partners

pr advisors

Impact Partners

Goldman Sachs

financial advisors

Goldman Sachs

Freshfields Bruckhaus Deringer

legal advisors to financial advisors

Freshfields Bruckhaus Deringer

Davis Polk & Wardwell

legal advisors

Davis Polk & Wardwell

Nordea Bank

financial advisors

Nordea Bank

Gordon Dyal & Co

financial advisors

Gordon Dyal & Co

Danske Bank

financial advisors

Danske Bank

Plesner

legal advisors

Plesner

Oxera

financial advisors

Oxera

Linklaters

legal advisors

Linklaters

FGS Global

pr advisors

FGS Global

Point Communications

pr advisors

Point Communications

Simpson Thacher & Bartlett

legal advisors to financial advisors

Simpson Thacher & Bartlett

FIH Partners

financial advisors

FIH Partners

or

Principals

CHR. HANSEN

target

CHR. HANSEN

NOVOZYMES AS

bidder

NOVOZYMES AS

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Novozymes completed the acquisition of Chr. Hansen for $12.3bn.